Price$25.11-0.37 (-1.45%)
2026-03-052026-06-08
Latest news
25 items- PRAvilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business OfficerAvilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of therapeutic areas and technologies at both private and public biopharmaceutical companies. In his role at Avilar, Dr. Muzikant will be responsible for corporate and business development as well as various business operations functions. This press release features multimedia. View the full release here: https://www.busi
- SECSEC Form 15-12B filed by Flexion Therapeutics, Inc.15-12B - Flexion Therapeutics Inc (0001419600) (Filer)
- SECSEC Form EFFECT filed by Flexion Therapeutics, Inc.EFFECT - Flexion Therapeutics Inc (0001419600) (Filer)
- INSIDERSEC Form 4 filed by Newtyn Management, Llc4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 3: New insider Newtyn Management, Llc claimed ownership of 5,900,000 shares3 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4: Stejbach Mark returned $107,364 worth of shares to the company (12,631 units at $8.50), closing all direct ownership in the company to cover taxes4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4: Milinazzo Alan returned $233,325 worth of shares to the company (27,450 units at $8.50), closing all direct ownership in the company to satisfy withholding tax4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4: Merrifield C Ann returned $161,500 worth of shares to the company (19,000 units at $8.50), closing all direct ownership in the company to cover withholding tax4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4: Lukatch Heath returned $76,500 worth of shares to the company (9,000 units at $8.50), closing all direct ownership in the company to satisfy tax liability4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4: Kwo Elizabeth returned $38,250 worth of shares to the company (4,500 units at $8.50), closing all direct ownership in the company (tax liability)4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4 filed by Koppikar Utpal4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4: Colella Samuel D returned $12,720,794 worth of shares to the company (1,496,564 units at $8.50), closing all direct ownership in the company (tax withholding)4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4: Canute Scott A returned $76,500 worth of shares to the company (9,000 units at $8.50), closing all direct ownership in the company (withholding obligation)4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4: Mahaffy Patrick J returned $338,504 worth of shares to the company (39,824 units at $8.50), closing all direct ownership in the company (withholding obligation)4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4: Levine Mark S. returned $1,134,631 worth of shares to the company (133,486 units at $8.50), closing all direct ownership in the company (for tax liability)4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4: Muzikant Adam returned $881,161 worth of shares to the company (103,666 units at $8.50), closing all direct ownership in the company to satisfy tax liability4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4: Wentworth Kerry returned $1,248,166 worth of shares to the company (146,843 units at $8.50), closing all direct ownership in the company (tax liability)4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4: Layman Melissa returned $883,626 worth of shares to the company (103,956 units at $8.50), closing all direct ownership in the company (tax withholding)4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4: Willwerth Christina returned $1,200,548 worth of shares to the company (141,241 units at $8.50), closing all direct ownership in the company (for withholding tax)4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4: Driscoll Frederick W returned $260,780 worth of shares to the company (30,680 units at $8.50), closing all direct ownership in the company to satisfy tax liability4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4: Andrews William T. returned $291,125 worth of shares to the company (34,250 units at $8.50), closing all direct ownership in the company to cover withholding tax4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- INSIDERSEC Form 4: Clayman Michael D. returned $9,541,675 worth of shares to the company (1,122,550 units at $8.50), closing all direct ownership in the company to satisfy withholding obligation4 - Flexion Therapeutics Inc (0001419600) (Issuer)
- SECSEC Form S-8 POS filed by Flexion Therapeutics, Inc.S-8 POS - Flexion Therapeutics Inc (0001419600) (Filer)
- SECSEC Form S-8 POS filed by Flexion Therapeutics, Inc.S-8 POS - Flexion Therapeutics Inc (0001419600) (Filer)
- SECSEC Form S-8 POS filed by Flexion Therapeutics, Inc.S-8 POS - Flexion Therapeutics Inc (0001419600) (Filer)
FLXN FAQ
8 questionsWhat does Flexion Therapeutics, Inc. do?
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the...Where does FLXN stock trade?
Flexion Therapeutics, Inc. (FLXN) is listed on NASDAQ.What sector and industry is FLXN in?
Flexion Therapeutics, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.When did Flexion Therapeutics, Inc. go public?
Flexion Therapeutics, Inc. (FLXN) completed its IPO in 2014.Does FLXN pay a dividend?
FLXN's most recent ex-dividend date was 2026-05-28 with a cash dividend of $0.19 per share. No future ex-date is on file yet.What are analysts saying about FLXN?
Flexion Therapeutics, Inc. has had 7 recent analyst actions on file. The most recent action was from Northland Capital Markets: Market Perform on 2021-11-19. Recent price targets range from $600.00 to $1800.00.What companies are similar to FLXN?
Notable peers in the same industry include DRNA (Dicerna Pharmaceuticals, Inc.), TRIL (Trillium Therapeutics Inc.), KDMN (Kadmon Holdings, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.), KIN (Kindred Biosciences, Inc.). Compare FLXN side-by-side with any of them on Quantisnow.How can I track FLXN on Quantisnow?
Quantisnow aggregates Flexion Therapeutics, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FLXN to receive live email and push alerts on every new disclosure.